WEED, Inc. (BUDZ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.49M is the value of all shares combined. Beta 0.80: the stock has moved about 20% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerWEED, Inc. (BUDZ) trades at $0.01. WEED, Inc. focuses on developing cannabis-derived compounds for treating human diseases. The company, formerly United Mines, Inc., changed its name in 2015 and is headquartered in Tucson, Arizona. Market cap: $1.49M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for BUDZ: BUDZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
WEED, Inc. (BUDZ) Healthcare & Pipeline Overview
WEED, Inc. is a specialty pharmaceutical company focused on the development and application of cannabis-derived compounds for treating human diseases. Operating in the healthcare sector, the company aims to capitalize on the growing market for cannabis-based therapeutics, though it currently faces significant profitability challenges.
What Is the Investment Thesis for BUDZ?
WEED, Inc. presents a high-risk, high-reward investment opportunity within the cannabis-based pharmaceutical sector. The company's focus on developing cannabis-derived treatments offers potential upside if it can successfully navigate the regulatory landscape and bring viable products to market. However, with a negative profit margin of -2292.8% and a negative gross margin of -9.0%, the company's financial performance raises concerns about its ability to sustain operations. Key catalysts include advancements in its drug development pipeline and potential regulatory changes favoring cannabis-based therapeutics. Investors should carefully weigh the potential for significant growth against the substantial financial and operational risks.
Based on FMP financials and quantitative analysis
BUDZ Key Highlights
Market capitalization of $1.49M indicates a micro-cap company with limited resources.
- P/E ratio of -4.01 reflects negative earnings, suggesting the company is currently unprofitable.
- Profit margin of -2292.8% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross margin of -9.0% indicates that the company's cost of goods sold exceeds its revenue, posing a substantial risk to its financial viability.
- Beta of 0.80 suggests the stock is less volatile than the market average, but this may be due to its limited trading activity.
Who Are BUDZ's Competitors?
BUDZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BQST BioQuest Corp. | $0.25 | 0.00% | $7.47M | — |
| UPC Universe Pharmaceuticals Inc. | $1.08 | -20.59% | 32 5-pillar | |
| BFRI Biofrontera Inc. | $0.53 | -7.02% | $7.87M | — |
| SXTC China SXT Pharmaceuticals, Inc. | $2.65 | +2.12% | — | |
| QNTM Quantum BioPharma Ltd. | $1.29 | -9.15% | $8.29M | 30 5-pillar |
| AKAN Akanda Corp. | $4.23 | +23.32% | $11.2M | — |
| COSM COSM | $2.81 | -2.09% | $14.1M | — |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $3.49 | -10.51% | $16.6M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BUDZ's Key Strengths?
Focus on cannabis-derived compounds for medical treatments.
- Potential first-mover advantage in specific therapeutic areas.
- Strategic shift towards a growing market segment.
- Low beta suggests relatively stable stock price.
What Are BUDZ's Weaknesses?
Negative profit and gross margins indicate financial instability.
- Small size and limited resources.
- Dependence on regulatory approvals and market acceptance.
- Limited information available on specific products or pipeline.
What Could Drive BUDZ Stock Higher?
Potential advancements in the development of cannabis-derived compounds for treating human diseases.
- Possible regulatory changes favoring cannabis-based therapeutics.
- Strategic partnerships with larger pharmaceutical companies or research institutions.
- Increasing acceptance and legalization of medical cannabis worldwide.
- Research and development efforts to create proprietary formulations.
What Are the Key Risks for BUDZ?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Negative profit and gross margins indicate financial instability.
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements and evolving regulations.
- Negative public perception of cannabis.
- Limited financial disclosure and transparency due to OTC listing.
What Are the Growth Opportunities for BUDZ?
- Expansion into New Therapeutic Areas: WEED, Inc. can explore new therapeutic applications for cannabis-derived compounds beyond its current focus. The market for cannabis-based treatments is expanding, with potential applications in areas such as pain management, mental health, and neurological disorders. Success in developing and commercializing treatments for these conditions could significantly increase the company's revenue and market share. The timeline for this growth opportunity depends on the pace of research and development, as well as regulatory approvals.
- Strategic Partnerships and Collaborations: WEED, Inc. can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate its drug development efforts and access additional resources. Collaborations can provide access to funding, expertise, and distribution channels, increasing the likelihood of successful product development and commercialization. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
- Geographic Expansion: As regulations surrounding cannabis-based treatments evolve, WEED, Inc. can expand its geographic reach by entering new markets. This could involve establishing operations in countries or regions with favorable regulatory environments or partnering with local distributors to market its products. The timeline for this growth opportunity depends on the pace of regulatory changes and the company's ability to navigate international markets.
- Development of Proprietary Formulations: WEED, Inc. can focus on developing proprietary formulations of cannabis-derived compounds to differentiate its products from competitors. This could involve creating unique delivery systems, optimizing dosages, or combining cannabis compounds with other therapeutic agents. Successful development of proprietary formulations could provide a competitive advantage and increase the company's pricing power. The timeline for this growth opportunity depends on the company's research and development capabilities.
- Capitalizing on the Growing Acceptance of Medical Cannabis: The increasing acceptance and legalization of medical cannabis worldwide presents a significant growth opportunity for WEED, Inc. As more countries and regions legalize medical cannabis, the market for cannabis-based treatments is expected to expand rapidly. WEED, Inc. can capitalize on this trend by developing and commercializing innovative products that meet the needs of patients and healthcare providers. The timeline for this growth opportunity depends on the pace of regulatory changes and the company's ability to adapt to evolving market conditions.
What Are BUDZ's Competitive Advantages?
- Proprietary formulations of cannabis-derived compounds (if any).
- Intellectual property protection through patents (if any).
- Strategic partnerships with established pharmaceutical companies (if any).
- First-mover advantage in specific therapeutic areas (if any).
What Does BUDZ Do?
WEED, Inc., originally incorporated in 1999 as United Mines, Inc., transitioned its focus to the development and application of cannabis-derived compounds in February 2015, adopting the name WEED, Inc. Headquartered in Tucson, Arizona, the company's core business revolves around researching and developing treatments for various human diseases using cannabis-derived compounds. Despite its efforts in the specialty and generic drug manufacturing industry, WEED, Inc. faces significant challenges, as reflected in its negative profit and gross margins. The company's small size, with only two employees, suggests a reliance on external partnerships or a highly focused operational model. Its evolution from United Mines, Inc. indicates a strategic shift to capitalize on the emerging cannabis therapeutics market.
What Products and Services Does BUDZ Offer?
- Develop cannabis-derived compounds for medical treatments.
- Research applications of cannabis in treating human diseases.
- Formulate cannabis-based pharmaceuticals.
- Potentially conduct clinical trials to evaluate drug efficacy.
- Seek regulatory approvals for its pharmaceutical products.
- Market and distribute approved cannabis-derived treatments.
How Does BUDZ Make Money?
- Research and development of cannabis-based pharmaceuticals.
- Potential revenue from licensing or selling proprietary formulations.
- Revenue from sales of approved cannabis-derived treatments.
- Partnerships and collaborations with other pharmaceutical companies.
What Industry Does BUDZ Operate In?
WEED, Inc. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, stringent regulatory requirements, and significant research and development costs. The increasing acceptance and legalization of cannabis for medical purposes has created a niche market for companies like WEED, Inc., focusing on cannabis-derived therapeutics. However, the company faces competition from both established pharmaceutical companies and other cannabis-focused businesses. The market is subject to evolving regulations and public perception, adding to the inherent risks.
Who Are BUDZ's Key Customers?
- Patients seeking alternative treatments for various diseases.
- Healthcare providers recommending cannabis-based therapies.
- Pharmacies dispensing cannabis-derived medications.
- Research institutions collaborating on clinical trials.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
How WEED, Inc. Is Valued
WEED, Inc. carries a market capitalization of $1.49M, placing it in the micro-cap category.
Company Profile
WEED, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tucson, United States.
Key Financial Metrics
Return on equity for WEED, Inc. stands at 147.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -8.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -46.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
WEED, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
8 transactions · 0 purchases, 8 sales, 0 other transactions · 1 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 28, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
BUDZ Financials
Bull Case vs Bear Case
Bull Case
- Focus on cannabis-derived compounds for medical treatments.
- Potential first-mover advantage in specific therapeutic areas.
- Strategic shift towards a growing market segment.
- Low beta suggests relatively stable stock price.
Bear Case
- Negative profit and gross margins indicate financial instability.
- Small size and limited resources.
- Dependence on regulatory approvals and market acceptance.
- Limited information available on specific products or pipeline.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BUDZ Latest News
No recent news available for BUDZ.
BUDZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BUDZ.
Price Targets
Wall Street price target analysis for BUDZ.
BUDZ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BUDZ; grades run from A+ (80-100) to F (below 30).
Leadership: Glenn E. Martin
CEO
Glenn E. Martin serves as the CEO of WEED, Inc., leading a small team of two employees. As the head of WEED, Inc., Martin is responsible for guiding the company's strategic direction in the development and application of cannabis-derived compounds for the treatment of human diseases. His leadership is crucial for navigating the complex regulatory landscape and driving the company's growth in the emerging cannabis therapeutics market.
Track Record: Due to limited information, Glenn E. Martin's specific achievements and strategic decisions at WEED, Inc. are not available. The company's financial performance, characterized by negative profit and gross margins, suggests significant challenges during his tenure. Further information is needed to assess his track record and contributions to the company's development.
BUDZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk due to the potential for fraud, manipulation, and lack of transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- High price volatility.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's legal standing and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company's history of operations since 1999.
- Focus on developing cannabis-derived compounds for medical treatments.
- Change of name to WEED, Inc. in 2015, indicating a strategic shift.
- Headquarters located in Tucson, Arizona.
- Existence of a CEO, Glenn E. Martin, although information is limited.
WEED, Inc. Healthcare Stock: Key Questions Answered
Is BUDZ a good stock to buy?
Stock Expert AI does not rate BUDZ buy, sell or hold. WEED, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BUDZ stock price today?
The last price recorded on this page for WEED, Inc. (BUDZ) is $0.01, as of the Nov 20, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about BUDZ stock?
Due to the company's OTC listing and limited analyst coverage, there is no readily available consensus view on WEED, Inc.'s stock.
What are the key factors to evaluate for BUDZ?
Evaluate BUDZ on fundamentals, analyst consensus, and risk factors. Gross margin of -9.0% indicates that the company's cost of goods sold exceeds its revenue, posing a substantial risk to its financial viability. Not financial advice.
How frequently does BUDZ data refresh on this page?
BUDZ's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BUDZ's recent stock price performance?
WEED, Inc. (BUDZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabis-derived compounds for medical treatments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BUDZ overvalued or undervalued right now?
WEED, Inc. (BUDZ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BUDZ before investing?
Before investing in WEED, Inc. (BUDZ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available on the company's specific products, clinical trials, and financial performance.
- OTC listing increases the risk of investing in this company.